Validating a Markov Model of Treatment for Hepatitis C Virus-related Hepatocellular Carcinoma

Summary

Objective: We created and validated a Markov model to simulate the prognosis with treatment for HCV-related hepatocellular carcinoma (HCC) for assessment of cost-effectiveness for alternative treatments of HCC.

Method: Markov state incorporated into the model consisted of the treatment as a surrogate for HCC stage and underlying liver function. Retrospective data of 793 patients from three university hospitals were used to determine Kaplan-Meier survival curves for each treatment and transition probabilities were derived from them.

Results: There was substantial overlap in the 95% CIs of the Markov model predicted and the Kaplan-Meier survival curves for each therapy. The predicted survival curves were also similar with those from the nationwide survey data supporting the external validity of our model.

Conclusions: Our Markov model estimates for prognosis with HCC have both internal and external validity and should be considered applicable for estimating cost-effectiveness related to HCC.

Keywords

Hepatocellular carcinoma - prognosis - survival rate - Markov model - validation

• References

• 1 Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med 2006; 45 (05) 229-233.
• 2 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 2 Suppl 1 S115-20.
• 3 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 9399 1907-1917.
• 4 Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol 2007; 34 2 Suppl 1 S12-20.
• 5 Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med 1982; 73 (06) 883-888.
• 6 Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision- making. Am J Med 1982; 73 (06) 889-897.
• 7 Ishida H, Inoue Y, Kurokawa F, Hino K, Okita K. Cost-effectiveness of screening program for Hepatitis C virus related hepatocellular carcinoma. Japan Journal of Medical Informatics 2002; 27 suppl 139-140.
• 8 Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M. et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37 (09) 676-691.
• 9 Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York: Wiley-Interscience; 2002
• 10 Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N. et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26 (06) 680-687.
• 11 Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98 (03) 679-690.
• 12 Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. Liver 2002; 22 (06) 479-485.
• 13 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19 (11) 1159-1172.
• 14 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3 (01) 75-84.
• 15 Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S. et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9 (07) 672-681.
• 16 Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101 (04) 422-434.
• 17 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H. et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008; 23 (03) 437-444.
• 18 Group formed to establish “Guidelines for evidence- based clinical practice for the treatment of liver cancer”. Clinical practice guidelines for hepatocellular carcinoma. Tokyo: Kanehara & Co., Ltd.; 2005
• 19 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y. et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 2004; 100 (11) 2415-2421.
• 20 Chevret S, Leporrier M, Chastang C. Measures of treatment effectiveness on tumour response and survival: a multi-state model approach. Stat Med 2000; 19 (06) 837-848.
• 21 Keiding N, Klein JP, Horowitz MM. Multi-state models and outcome prediction in bone marrow transplantation. Stat Med 2001; 20 (12) 1871-1885.
• 22 Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58 (04) 947-952.
• 23 Faddy MJ, McClean SI. Markov chain modelling for geriatric patient care. Methods Inf Med 2005; 44 (03) 369-373.
• 24 Smolen HJ, Cohen DJ, Samsa GP, Toole JF, Klein RW, Furiak NM. et al. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis. Value Health 2007; 10 (06) 489-497.
• 25 Vanness DJ, Kim WR. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Health Econ 2002; 11 (06) 551-566.
• 26 Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3 (04) 419-458.
• 27 Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (04) 322-238.
• 28 Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004; 10 2 Suppl 1 S46-52.
• 29 Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent advances. Br Med Bull. 2005 75-76 15-28
• 30 Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis 2006; 26 (03) 248-253.
• 31 Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 13 (03) 391-399.